Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Apr;63(4):335-43.
doi: 10.1007/s00228-007-0268-6. Epub 2007 Feb 21.

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction

Tom Schalekamp  1 , Johanna H H van Geest-Daalderop, Mark H H Kramer, Angelique T M van Holten-Verzantvoort, Anthonius de Boer
Affiliations

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction

Tom Schalekamp et al. Eur J Clin Pharmacol. 2007 Apr.

Abstract

Objective: The objective of our study was to examine the management of the interaction between acenocoumarol or phenprocoumon and several antibiotics by anticoagulation clinics and to compare the consequences of this interaction on users of co-trimoxazole with those for users of other antibiotics.

Methods: A follow-up study was conducted at four anticoagulation clinics in The Netherlands. Data on measurements of the International Normalised Ratio (INR), application of a preventive dose reduction (PDR) of the coumarin anticoagulant, fever and time within or outside the therapeutic INR range were collected.

Results: The study cohort consisted of 326 subjects. A PDR was given more often to users of co-trimoxazole PDR than to users of other antibiotics. The PDR in co-trimoxazole users resulted in a significantly reduced risk of both moderate overanticoagulation (INR >4.5) and severe overanticoagulation (INR >6.0) compared with no PDR, with odds ratios (ORs) of 0.06 [95% confidence interval (CI): 0.01-0.51] and 0.09 (95% CI: 0.01-0.92), respectively. In co-trimoxazole users without PDR, the risk of overanticoagulation was significantly increased compared with users of other antibiotics. All co-trimoxazole users spent significantly more time under the therapeutic INR range during the first 6 weeks after the course than users of other antibiotics.

Conclusion: PDR is effective in preventing overanticoagulation in co-trimoxazole users, but results in a significantly prolonged period of underanticoagulation after the course. Avoidance of concomitant use of co-trimoxazole with acenocoumarol or phenprocoumon seems to be a safer approach than management of the interaction between these drugs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anonymous (2003) Standaard Afhandeling Cumarine Interacties. Available at: http://www.fnt.nl. 2003
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '11149144', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11149144/'}]}
    2. Chafin CC, Ritter BA, James A, Self TH (2000) Hospital admission due to warfarin potentiation by TMP-SMX. Nurse Pract 25(12):73–75 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '0', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/0/'}]}
    2. Cook DE, Ponte CD (1994) Suspected trimethoprim/sulfamethoxazole-induced hypothrombinemia. J Pharm Pract 39(6):589–591 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1182/blood-2004-06-2111', 'is_inner': False, 'url': 'https://doi.org/10.1182/blood-2004-06-2111'}, {'type': 'PubMed', 'value': '15358623', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15358623/'}]}
    2. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2):645–649 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10832939', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10832939/'}]}
    2. Demirkan K, Stephens MA, Newman KP, Self TH (2000) Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 93(5):448–454 - PubMed